Literature DB >> 6841033

Upper dorsal sympathectomy for palmar hyperhidrosis.

A Bass, S Inovrotzlavski, R Adar.   

Abstract

The treatment results in 133 patients who underwent bilateral upper dorsal sympathectomy (BUDS) for palmar hyperhidrosis (HH) are reported. Group 1 (67 patients) was followed for 5 to 10 yr (mean 7) and Group 2 (66 patients) was followed for 1 to 4 yr (mean 2). Early results and complications, early and late sequelae, late recurrence and patient satisfaction with the results of the operation were analyzed. The immediate success rate was 98%, and late recurrence of HH was noted in 5.3% of the patients. The incidence of technical complications was lower in Group 2 than in Group 1, otherwise both groups were similar. Persistent, severe Horner's syndrome was present in only one patient at late follow-up. Troublesome compensatory HH persisted in one-third of the patients. Overall patient satisfaction was good, and only 10 patients regretted having undergone the operation. BUDS appears to be the best solution for severe palmar HH in properly selected patients.

Entities:  

Mesh:

Year:  1983        PMID: 6841033

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  4 in total

1.  The long-term results of upper dorsal sympathetic ganglionectomy and endoscopic thoracic sympathectomy for palmar hyperhidrosis.

Authors:  C L Lin; C P Yen; S L Howng
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Phantom sweating: a novel autonomic paresthesia.

Authors:  Lindsey Lair; Christopher Gibbons; Roy Freeman
Journal:  Clin Auton Res       Date:  2008-10-11       Impact factor: 4.435

3.  Thoracic endoscopic T2-T3 sympathectomy in palmar hyperhidrosis: experience of 112 cases.

Authors:  S H Chou; S H Lee; E L Kao
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

4.  Thoracic endoscopic sympathectomy for palmar hyperhidrosis in an adolescent female.

Authors:  S P Salob; D J Atherton; E M Kiely
Journal:  J R Soc Med       Date:  1991-02       Impact factor: 18.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.